Wall Street analysts expect Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) to report earnings of ($0.72) per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Bellicum Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.76) and the highest is ($0.63). Bellicum Pharmaceuticals reported earnings of ($0.66) per share in the same quarter last year, which suggests a negative year over year growth rate of 9.1%. The business is expected to issue its next quarterly earnings report on Wednesday, November 8th.
According to Zacks, analysts expect that Bellicum Pharmaceuticals will report full-year earnings of ($3.00) per share for the current fiscal year, with EPS estimates ranging from ($3.09) to ($2.81). For the next financial year, analysts forecast that the firm will report earnings of ($2.86) per share, with EPS estimates ranging from ($3.18) to ($2.55). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Bellicum Pharmaceuticals.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by $0.09. Bellicum Pharmaceuticals had a negative return on equity of 70.74% and a negative net margin of 17,957.31%. During the same period last year, the company posted ($0.61) EPS.
A number of analysts have recently issued reports on BLCM shares. BidaskClub upgraded Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. Raymond James Financial, Inc. reiterated a “buy” rating on shares of Bellicum Pharmaceuticals in a research report on Tuesday, June 27th. Cantor Fitzgerald reiterated an “overweight” rating and set a $35.00 price target on shares of Bellicum Pharmaceuticals in a research report on Monday, June 26th. ValuEngine downgraded Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, August 11th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $16.00 price target (down previously from $18.00) on shares of Bellicum Pharmaceuticals in a research report on Thursday, August 10th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $26.20.
ILLEGAL ACTIVITY WARNING: “-$0.72 EPS Expected for Bellicum Pharmaceuticals, Inc. (BLCM) This Quarter” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://sportsperspectives.com/2017/09/12/0-72-eps-expected-for-bellicum-pharmaceuticals-inc-blcm-this-quarter.html.
In related news, insider David M. Spencer sold 10,000 shares of the firm’s stock in a transaction dated Monday, July 10th. The stock was sold at an average price of $11.54, for a total transaction of $115,400.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Ken Moseley sold 13,823 shares of the firm’s stock in a transaction dated Thursday, July 13th. The shares were sold at an average price of $12.26, for a total value of $169,469.98. Following the transaction, the vice president now directly owns 14,314 shares in the company, valued at $175,489.64. The disclosure for this sale can be found here. Over the last three months, insiders have sold 24,260 shares of company stock worth $290,048. 23.30% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. California State Teachers Retirement System raised its holdings in shares of Bellicum Pharmaceuticals by 16.7% during the 2nd quarter. California State Teachers Retirement System now owns 48,146 shares of the biopharmaceutical company’s stock valued at $562,000 after buying an additional 6,900 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Bellicum Pharmaceuticals by 26.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,319 shares of the biopharmaceutical company’s stock valued at $261,000 after buying an additional 4,684 shares in the last quarter. State Street Corp raised its holdings in shares of Bellicum Pharmaceuticals by 16.6% during the 2nd quarter. State Street Corp now owns 416,966 shares of the biopharmaceutical company’s stock valued at $4,872,000 after buying an additional 59,321 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Bellicum Pharmaceuticals by 223.5% during the 2nd quarter. Goldman Sachs Group Inc. now owns 138,000 shares of the biopharmaceutical company’s stock valued at $1,612,000 after buying an additional 95,336 shares in the last quarter. Finally, HighTower Advisors LLC purchased a new position in shares of Bellicum Pharmaceuticals during the 2nd quarter valued at about $448,000. 55.73% of the stock is currently owned by institutional investors.
Shares of Bellicum Pharmaceuticals (NASDAQ:BLCM) traded up 0.4878% on Tuesday, reaching $10.3201. The company’s stock had a trading volume of 71,712 shares. The stock’s market cap is $342.90 million. Bellicum Pharmaceuticals has a 12 month low of $7.41 and a 12 month high of $23.11. The firm’s 50-day moving average price is $9.62 and its 200-day moving average price is $11.76.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.